Formulation: A solid
Formal Name: (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-(((2R,3R,4S,5S,6R)-3,5-dihydroxy-6-methyl-4-(methyl(methyl-d3)amino)tetrahydro-2H-pyran-2-yl)oxy)-7-(2-((3S,5R)-3,5-dimethylpiperidin-1-yl)ethyl)-16-ethyl-4-hydroxy-15-((((2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)-5,9,13-trimethyloxacyclohexadeca-11,13-diene-2,10-dione
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C46H77D3N2O13
Formula Weight: 872,2
Shelf life (days): 1460
CAS Number: 2714486-61-8
Notes: Tilmicosin-d3 is intended for use as an internal standard for the quantification of tilmicosin (Item No. 18190) by GC- or LC-MS. Tilmicosin is a macrolide antibiotic.{27769} It is active against macrolide-susceptible strains of M. haemolytica, P. multocida, and E. coli (MICs = 4, 4, and 128 µM, respectively), as well as a hyperpermeable strain of E. coli (MIC = 2 µM), and inhibits bacterial protein synthesis (IC50 = 0.36 µM). Tilmicosin (75 mg/kg) increases serum creatine kinase (CK), the MB isoform of CK (CK-MB), and malondialdehyde (MDA) levels in mice, indicating cardiotoxicity.{61661} Formulations containing tilmicosin have been used in the treatment of respiratory diseases in sheep and cattle.
English
Deutsch
